Pooling overdispersed binomial data to estimate event rate

BackgroundThe beta-binomial model is one of the methods that can be used to validly combine event rates from overdispersed binomial data. Our objective is to provide a full description of this method and to update and broaden its applications in clinical and public health research.MethodsWe describe the statistical theories behind the beta-binomial model and the associated estimation methods. We supply information about statistical software that can provide beta-binomial estimations. Using a published example, we illustrate the application of the beta-binomial model when pooling overdispersed binomial data.ResultsIn an example regarding the safety of oral antifungal treatments, we had 41 treatment arms with event rates varying from 0% to 13.89%. Using the beta-binomial model, we obtained a summary event rate of 3.44% with a standard error of 0.59%. The parameters of the beta-binomial model took the values of 1.24 for alpha and 34.73 for beta.ConclusionThe beta-binomial model can provide a robust estimate for the summary event rate by pooling overdispersed binomial data from different studies. The explanation of the method and the demonstration of its applications should help researchers incorporate the beta-binomial method as they aggregate probabilities of events from heterogeneous studies.

[1]  Griffiths Da.  Maximum likelihood estimation for the beta-binomial distribution and an application to the household distribution of the total number of cases of a disease. , 1973 .

[2]  A. Woscoff,et al.  Itraconazole versus terbinafine (LAMISIL®): which is better for the treatment of onychomycosis? , 1997 .

[3]  B. Piraccini,et al.  Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. , 1996, Journal of the American Academy of Dermatology.

[4]  H. Zaun,et al.  Treatment of toenail onychomycosis. A randomized, double-blind study with terbinafine and griseofulvin. LAGOS II Study Group. , 1995, Archives of dermatology.

[5]  David M. Drukker,et al.  On boundary-value likelihood-ratio tests , 2001 .

[6]  M. Bräutigam,et al.  Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. LAGOS III Study Group. , 1995, Journal of the American Academy of Dermatology.

[7]  The statistical power of replications in difference tests , 2003 .

[8]  D. Bates,et al.  Newton-Raphson and EM Algorithms for Linear Mixed-Effects Models for Repeated-Measures Data , 1988 .

[9]  T. Louis,et al.  Bayes and Empirical Bayes Methods for Data Analysis. , 1997 .

[10]  L. Dubertret,et al.  Comparative multicentre double-blind study of terbinafine (250 mg per day) versus griseofulvin (1 g per day) in the treatment of dermatophyte onychomycosis , 1997 .

[11]  V. Voravutinon.  Oral treatment of tinea corporis and tinea cruris with terbinafine and griseofulvin: a randomized double blind comparative study. , 1993, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[12]  M. De Backer,et al.  Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. , 1998, Journal of American Academy of Dermatology.

[13]  R. Hay,et al.  A comparison of 2 weeks of terbinafine 250 mg/day with 4 weeks of itraconazole 1OO mg/day in plantar‐type tinea pedis , 1995, The British journal of dermatology.

[14]  Martin Jansche,et al.  Parametric Models of Linguistic Count Data , 2003, ACL.

[15]  T. Kurth,et al.  The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. , 2007, The American journal of medicine.

[16]  J. Leyden,et al.  Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. , 1997, Journal of the American Academy of Dermatology.

[17]  N. Zaias,et al.  Treatment of chronic moccasin-type tinea pedis with terbinafine: a double-blind, placebo-controlled trial. , 1990, Journal of the American Academy of Dermatology.

[18]  E. Alpsoy,et al.  Intermittent Therapy with Terbinafine for Dermatophyte Toe‐Onychomycosis: A New Approach , 1996, The Journal of dermatology.

[19]  Tom Leonard,et al.  A Bayesian Approach to Some Multinomial Estimation and Pretesting Problems , 1977 .

[20]  J. Czernielewski,et al.  A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region , 2000, The British journal of dermatology.

[21]  B. L. Andersen,et al.  Oral terbinafine in toenail dermatophytosis. A double-blind, placebo-controlled multicenter study with 12 months' follow-up. , 1997, Acta dermato-venereologica.

[22]  C. Lynde,et al.  Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. , 2001, Journal of the American Academy of Dermatology.

[23]  D. Ennis,et al.  THE BETA‐BINOMIAL MODEL: ACCOUNTING FOR INTER‐TRIAL VARIATION IN REPLICATED DIFFERENCE AND PREFERENCE TESTS , 1998 .

[24]  M. Crijns,et al.  A randomized treatment duration‐finding study of terbinafine in onychomycosis , 1992, The British journal of dermatology.

[25]  Aditya K. Gupta,et al.  Efficacy of Itraconazole, Terbinafine, Fluconazole, Griseofulvin and Ketoconazole in the Treatment of Scopulariopsis brevicaulis Causing Onychomycosis of the Toes , 2001, Dermatology.

[26]  Yuhlong Lio,et al.  A note on bayesian estimation and prediction for the beta-binomial model , 1999 .

[27]  L. I. Díez,et al.  A comparative double‐blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris , 1990 .

[28]  R. Savin.  Successful treatment of chronic tinea pedis (moccasin type) with terbinafine (Lamisil) , 1989, Clinical and experimental dermatology.

[29]  R. Schopf,et al.  Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection , 1995, BMJ.

[30]  Christy Chuang-Stein,et al.  An Application of the Beta-Binomial Model to Combine and Monitor Medical Event Rates in Clinical Trials , 1993 .

[31]  Nagaraj K. Neerchal,et al.  Large cluster results for two parametric multinomial extra variation models , 1998 .

[32]  G. Levy,et al.  Short-term itraconazole versus terbinafine in the treatment of tinea pedis or manus. , 1998, International journal of dermatology.

[33]  E. Evans,et al.  Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. , 1999, BMJ.

[34]  D. Massart,et al.  Two‐week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): a double‐blind, multicentre study , 1994, The British journal of dermatology.

[35]  A. Rukhin.  Bayes and Empirical Bayes Methods for Data Analysis , 1997 .

[36]  D. Griffiths.  Maximum likelihood estimation for the beta-binomial distribution and an application to the household distribution of the total number of cases of a disease. , 1973, Biometrics.

[37]  角田 亮子,et al.  プロダクトレビュー Lippincott Williams & Wilkinsの電子ジャーナル , 2007 .

[38]  David R. Cox,et al.  Some remarks on overdispersion , 1983 .

[39]  H. Degreef,et al.  Randomized double-blind comparison of short-term itraconazole and terbinafine therapy for toenail onychomycosis. , 1999, Acta dermato-venereologica.

[40]  A. Akar,et al.  An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis , 2002, The Journal of dermatological treatment.

[41]  Joel C. Kleinman,et al.  Proportions with Extraneous Variance: Single and Independent Samples , 1973 .

[42]  S. López Gómez,et al.  A comparative double‐blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris , 1990, Clinical and experimental dermatology.

[43]  P. Nordin,et al.  Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. , 1995, Journal of the American Academy of Dermatology.

[44]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[45]  E. Evans,et al.  Treatment of dermatophyte infection of the finger‐ and toe‐nails with terbinafine (SF 86‐327, Lamisil), an orally active fungicidal agent , 1989, The British journal of dermatology.

[46]  E. Evans,et al.  Short term treatment of dermatophyte onychomycosis with terbinafine. , 1992, BMJ.

[47]  R. Arenas,et al.  OPEN RANDOMIZED COMPARISON OE ITRACONAZOLE VERSUS TERBINAEINE IN ONYCHOMYCOSIS , 1995, International journal of dermatology.

[48]  B. Sigurgeirsson,et al.  Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis , 1999 .

[49]  R. Tarone,et al.  Testing the goodness of fit of the binomial distribution , 1979 .

[50]  J. G. Skellam.  A Probability Distribution Derived from the Binomial Distribution by Regarding the Probability of Success as Variable between the Sets of Trials , 1948 .

[51]  Paulo Guimarães.  A Simple Approach to Fit the Beta-binomial Model , 2005 .

[52]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[53]  Peter Congdon,et al.  Applied Bayesian Modelling , 2003 .

[54]  D. Hogan.  Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. , 1995, Journal of the American Academy of Dermatology.

[55]  S. Paul.  Analysis of proportions of affected foetuses in teratological experiments. , 1982, Biometrics.

[56]  M. Bräutigam,et al.  Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double‐blind trial comparing 6 and 12 weeks therapy , 1997, The British journal of dermatology.

[57]  Jack C. Lee,et al.  Bayesian Estimation and Prediction for the Beta-Binomial Model , 1987 .

[58]  J. Marley,et al.  Terbinafine in onychomycosis of the toenail: a novel treatment protocol. , 1995, Journal of the American Academy of Dermatology.

[59]  Robert L. Strawderman,et al.  Use of the Probability Integral Transformation to Fit Nonlinear Mixed-Effects Models With Nonnormal Random Effects , 2006 .

[60]  W W Piegorsch,et al.  On a Likelihood‐Based Goodness‐of‐Fit Test of the Beta‐Binomial Model , 2000, Biometrics.

[61]  Dorothy A. Anderson.  SOME MODELS FOR OVERDISPERSED BINOMIAL DATA , 1988 .

[62]  T. Rantanen,et al.  A double‐blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil®) with fluconazole (Diflucan®) in the treatment of onychomycosis , 2000, The British journal of dermatology.

[63]  T. Kurth,et al.  The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: a meta-analysis. , 2008, Lung cancer.

[64]  K Y Liang,et al.  On testing departure from the binomial and multinomial assumptions. , 1989, Biometrics.

[65]  E. Warshaw,et al.  Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial. , 2005, Journal of the American Academy of Dermatology.

[66]  S. Avner,et al.  Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis , 2005, The Journal of dermatological treatment.